Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor.
Schleinitz
N
N
Ebbo
M
M
Mazodier
K
K
Poullin
P
P
Bernit
E
E
Veit
V
V
Veyradier
A
A
Fakhouri
F
F
Kaplanski
G
G
Harle
J-R
JR
D051722:ADAM Proteins / Q000276:immunology*; D000071120:ADAMTS13 Protein; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D010951:Plasma Exchange; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000276:immunology / Q000628:therapy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D000069283:Rituximab; D055502:Secondary Prevention
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D000069283:Rituximab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human